References
- Menter A, Griffiths CEM. Current and future management of psoriasis. Lancet. 2007;370:272–284.
- Naldi L, Raho G. Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009;14:145–163.
- Naldi L, Svensson A, Zenoni D, Diepgen T, Elsner P, Grob JJ, . Comparators, study duration, outcome measures and sponsorship in therapeutic trials of psoriasis: Update of the EDEN Psoriasis Survey 2001–2006. Br J Dermatol. Epub 2009 Sept 24.
- US Department of Health and Human Services, Food and Drug Administration. Guidance for Industry – E 10 Choice of control group and related issues in clinical trials. Rockville, MD: Office of Training and Communication, Division of Drug Information, Center for Drug Evaluation and Research; May 2001. Available from: http://www.fda.gov/RegulatoryInformation/Guidances/ucm125802.htm.
- Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. London: European Medicines Agency; November 2004. Available from: http://www.ema.europa.eu/pdfs/human/ewp/245402en.pdf.
- Wittowski K, Leonardi C, Gottlieb A, Menter A, Krueger G, Tebbey P, . Empirical evidence for the clinical symptoms of skin, nails, and joints manifesting independently in patients with concomitant psoriasis and psoriatic arthritis. 2010 (submitted for publication: Arthritis & Rheumatism).